person · Reporting owner

DeMont Ross D

Disclosed activity across 3 companies

Tapewire entity: 87426
SEC CIK: 0001360838

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
SAFEGUARD SCIENTIFICS INCSFE · Entity 9612	Director	January 30, 2024	January 31, 2024
SIERRA MONITOR CORP /CA/SRMC · Entity 157272	Director	May 20, 2019	May 23, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

SAFEGUARD SCIENTIFICS INC

Report date January 30, 2024 · Filed January 31, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	287,256	Reported balance After 2024-01-30 transaction · row 1 1 source row Row 1 · 2024-01-30 · Grant · Acquired 20,775 · Balance 287,256 F2: The securities reported in Table I were awarded to the reporting person in lieu of quarterly fees for service on the Issuer's Board of Directors, which fees are paid in arrears following the end of the quarter.
Common StockSEC Table I · non-derivative	IndirectHeld by spouse	12,000	Reported balance Holding disclosure · report date 2024-01-30 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 12,000
Common StockSEC Table I · non-derivative	IndirectHeld in 401(k) account	30,000	Reported balance Holding disclosure · report date 2024-01-30 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 30,000
Common StockSEC Table I · non-derivative	IndirectHeld by Kenneth Rainin Foundation	301,722	Reported balance Holding disclosure · report date 2024-01-30 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 301,722 F1: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or any other purpose.

F2: The securities reported in Table I were awarded to the reporting person in lieu of quarterly fees for service on the Issuer's Board of Directors, which fees are paid in arrears following the end of the quarter.

SIERRA MONITOR CORP /CA/

Report date May 20, 2019 · Filed May 23, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
COMMON STOCKSEC Table I · non-derivative	Direct	0	Reported balance After 2019-05-20 transaction · row 1 1 source row Row 1 · 2019-05-20 · Disposition to issuer · Disposed 200,000 · Balance 0 F1: Shares of Issuer common stock were cancelled and disposed at the effective time of the merger of Gateway Merger Sub, Inc. ("Merger Sub"), an indirect, wholly owned subsidiary of MSA Safety Incorporated ("MSA"), with and into the Issuer, pursuant to that certain Agreement and Plan of Merger dated March 28, 2019, among the Issuer, MSA and Merger Sub as a result of which Issuer became an indirect wholly owned subsidiary of MSA, in exchange for a cash payment of $3.25 per share.

Filing footnotes · ownership attribution and instrument terms

F1: Shares of Issuer common stock were cancelled and disposed at the effective time of the merger of Gateway Merger Sub, Inc. ("Merger Sub"), an indirect, wholly owned subsidiary of MSA Safety Incorporated ("MSA"), with and into the Issuer, pursuant to that certain Agreement and Plan of Merger dated March 28, 2019, among the Issuer, MSA and Merger Sub as a result of which Issuer became an indirect wholly owned subsidiary of MSA, in exchange for a cash payment of $3.25 per share.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ALIMERA SCIENCES INC

Report date September 16, 2024 · Filed September 18, 2024

Section 16 reporting ended · disclosed 2024-09-18. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.99 · Expires 2033-10-01	Direct	0	Reported balance After 2024-09-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-09-16 · Disposition to issuer · Disposed 50,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of June 21, 2024 (the "Merger Agreement"), by and among the Issuer, ANI Pharmaceuticals, Inc., a Delaware corporation ("Parent") and ANIP Merger Sub INC., a Delaware corporation and a wholly owned indirect subsidiary of Parent, as of the effective time of the merger (the "Effective Time"), at the Effective Time, each stock option granted by the Issuer to purchase shares (each, an "Option") that was outstanding and unvested immediately prior to the Effective Time vested in full, and each Option that was outstanding and unexercised which had a per share exercise price that was less than ) $5.50 in cash, without interest (such amount, the "Closing Cash Consideration") was converted into the right to receive the sum of an amount in cash (without interest and subject to deduction for any required withholding as contemplated in the Merger Agreement) equal to: F2: (A) the excess, if any, of the Closing Cash Consideration over the exercise price per share of such Option; multiplied by the number of shares underlying such Option and (B) one contingent value right ("CVR") representing the right to receive contingent cash payments subject to the achievement of certain milestones and the terms and conditions set forth in a contingent value rights agreement entered into between Parent and a rights agent.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of June 21, 2024 (the "Merger Agreement"), by and among the Issuer, ANI Pharmaceuticals, Inc., a Delaware corporation ("Parent") and ANIP Merger Sub INC., a Delaware corporation and a wholly owned indirect subsidiary of Parent, as of the effective time of the merger (the "Effective Time"), at the Effective Time, each stock option granted by the Issuer to purchase shares (each, an "Option") that was outstanding and unvested immediately prior to the Effective Time vested in full, and each Option that was outstanding and unexercised which had a per share exercise price that was less than ) $5.50 in cash, without interest (such amount, the "Closing Cash Consideration") was converted into the right to receive the sum of an amount in cash (without interest and subject to deduction for any required withholding as contemplated in the Merger Agreement) equal to:

F2: (A) the excess, if any, of the Closing Cash Consideration over the exercise price per share of such Option; multiplied by the number of shares underlying such Option and (B) one contingent value right ("CVR") representing the right to receive contingent cash payments subject to the achievement of certain milestones and the terms and conditions set forth in a contingent value rights agreement entered into between Parent and a rights agent.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 16, 2024 Filed Sep 18, 2024 21:52 UTC	ALIMERA SCIENCES INC ALIM · Entity 11664	Disposition to issuerStock Option (Right to Buy) · Derivative	50,000	Not disclosed Strike: $2.99	Not disclosed	Disclosure SEC source: 0001104659-24-101106 · tm2424353-2_4seq1.xml · derivative · entry 1 DeMont Ross D · CIK 0001360838 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2033-10-01 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated as of June 21, 2024 (the "Merger Agreement"), by and among the Issuer, ANI Pharmaceuticals, Inc., a Delaware corporation ("Parent") and ANIP Merger Sub INC., a Delaware corporation and a wholly owned indirect subsidiary of Parent, as of the effective time of the merger (the "Effective Time"), at the Effective Time, each stock option granted by the Issuer to purchase shares (each, an "Option") that was outstanding and unvested immediately prior to the Effective Time vested in full, and each Option that was outstanding and unexercised which had a per share exercise price that was less than ) $5.50 in cash, without interest (such amount, the "Closing Cash Consideration") was converted into the right to receive the sum of an amount in cash (without interest and subject to deduction for any required withholding as contemplated in the Merger Agreement) equal to: F2 · price: (A) the excess, if any, of the Closing Cash Consideration over the exercise price per share of such Option; multiplied by the number of shares underlying such Option and (B) one contingent value right ("CVR") representing the right to receive contingent cash payments subject to the achievement of certain milestones and the terms and conditions set forth in a contingent value rights agreement entered into between Parent and a rights agent. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated as of June 21, 2024 (the "Merger Agreement"), by and among the Issuer, ANI Pharmaceuticals, Inc., a Delaware corporation ("Parent") and ANIP Merger Sub INC., a Delaware corporation and a wholly owned indirect subsidiary of Parent, as of the effective time of the merger (the "Effective Time"), at the Effective Time, each stock option granted by the Issuer to purchase shares (each, an "Option") that was outstanding and unvested immediately prior to the Effective Time vested in full, and each Option that was outstanding and unexercised which had a per share exercise price that was less than ) $5.50 in cash, without interest (such amount, the "Closing Cash Consideration") was converted into the right to receive the sum of an amount in cash (without interest and subject to deduction for any required withholding as contemplated in the Merger Agreement) equal to: F2 · derivative.exercise_date: (A) the excess, if any, of the Closing Cash Consideration over the exercise price per share of such Option; multiplied by the number of shares underlying such Option and (B) one contingent value right ("CVR") representing the right to receive contingent cash payments subject to the achievement of certain milestones and the terms and conditions set forth in a contingent value rights agreement entered into between Parent and a rights agent. Read SEC document
January 30, 2024 Filed Jan 31, 2024 14:19 UTC	SAFEGUARD SCIENTIFICS INC SFE · Entity 9612	GrantCommon Stock	20,775	$0.71	$14,750.25	Disclosure SEC source: 0001437749-24-002626 · rdgdoc.xml · nonDerivative · entry 1 DeMont Ross D · CIK 0001360838 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 287,256 F2 · price: The securities reported in Table I were awarded to the reporting person in lieu of quarterly fees for service on the Issuer's Board of Directors, which fees are paid in arrears following the end of the quarter. Read SEC document
October 16, 2023 Filed Oct 17, 2023 14:44 UTC	SAFEGUARD SCIENTIFICS INC SFE · Entity 9612	GrantCommon Stock	14,327	$1.11	$15,902.97	Disclosure SEC source: 0001437749-23-028341 · rdgdoc.xml · nonDerivative · entry 1 DeMont Ross D · CIK 0001360838 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 266,481 F2 · price: The securities reported in Table I were awarded to the reporting person in lieu of quarterly fees for service on the Issuer's Board of Directors, which fees are paid in arrears following the end of the quarte Read SEC document
October 02, 2023 Filed Oct 4, 2023 17:28 UTC	ALIMERA SCIENCES INC ALIM · Entity 11664	GrantStock Option (Right to Buy) · Derivative	50,000	$0.00 Strike: $2.99	$0.00	Disclosure SEC source: 0000950170-23-051984 · ownership.xml · derivative · entry 1 DeMont Ross D · CIK 0001360838 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-10-01 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments beginning on August 1, 2023. Vests in full on the earlier of August 1, 2024 or the date of the Issuer's 2024 annual meeting of stockholders, provided the Reporting Person provides continuous service to the Issuer through such date, with the final installment adjusted as necessary to avoid any fractional shares in any installment. Read SEC document
July 17, 2023 Filed Jul 18, 2023 16:52 UTC	SAFEGUARD SCIENTIFICS INC SFE · Entity 9612	GrantCommon Stock	9,407	$1.44	$13,499.05	Disclosure SEC source: 0001437749-23-020111 · rdgdoc.xml · nonDerivative · entry 1 DeMont Ross D · CIK 0001360838 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 252,154 F2 · price: The securities reported in Table I were awarded to the reporting person in lieu of quarterly fees for service on the Issuer's Board of Directors, which fees are paid in arrears following the end of the quarte Read SEC document
June 30, 2023 Filed Jun 30, 2023 14:52 UTC	SAFEGUARD SCIENTIFICS INC SFE · Entity 9612	GrantCommon Stock	44,497	$0.00	$0.00	Disclosure SEC source: 0001437749-23-018981 · rdgdoc.xml · nonDerivative · entry 1 DeMont Ross D · CIK 0001360838 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 242,747 Read SEC document
April 17, 2023 Filed Apr 19, 2023 13:13 UTC	SAFEGUARD SCIENTIFICS INC SFE · Entity 9612	GrantCommon Stock	8,613	$1.90	$16,364.70	Disclosure SEC source: 0001437749-23-010613 · rdgdoc.xml · nonDerivative · entry 1 DeMont Ross D · CIK 0001360838 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,250 F2 · price: The securities reported in Table I were awarded to the reporting person in lieu of quarterly fees for service on the Issuer's Board of Directors, which fees are paid in arrears following the end of the quarter. Read SEC document
January 17, 2023 Filed Jan 18, 2023 19:06 UTC	SAFEGUARD SCIENTIFICS INC SFE · Entity 9612	GrantCommon Stock	4,956	$3.13	$15,487.50	Disclosure SEC source: 0001437749-23-001202 · rdgdoc.xml · nonDerivative · entry 1 DeMont Ross D · CIK 0001360838 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,637 F2 · price: The securities reported in Table I were awarded to the reporting person in lieu of quarterly fees for service on the Issuer's Board of Directors, which fees are paid in arrears following the end of the quarter. Read SEC document
October 17, 2022 Filed Oct 18, 2022 14:45 UTC	SAFEGUARD SCIENTIFICS INC SFE · Entity 9612	GrantCommon Stock	3,981	$3.59	$14,291.79	Disclosure SEC source: 0001437749-22-024293 · rdgdoc.xml · nonDerivative · entry 1 DeMont Ross D · CIK 0001360838 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,681 F2 · price: The securities reported in Table I were awarded to the reporting person in lieu of quarterly fees for service on the Issuer's Board of Directors, which fees are paid in arrears following the end of the quarter. Read SEC document
July 15, 2022 Filed Jul 18, 2022 17:06 UTC	SAFEGUARD SCIENTIFICS INC SFE · Entity 9612	GrantCommon Stock	1,758	$3.86	$6,785.88	Disclosure SEC source: 0001437749-22-017242 · rdgdoc.xml · nonDerivative · entry 1 DeMont Ross D · CIK 0001360838 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,700 F2 · price: The securities reported in Table I were awarded to the reporting person in lieu of quarterly fees for service on the Issuer's Board of Directors, which fees are paid in arrears following the end of the quarter. Read SEC document
July 01, 2022 Filed Jul 1, 2022 16:40 UTC	SAFEGUARD SCIENTIFICS INC SFE · Entity 9612	GrantCommon Stock	18,942	$0.00	$0.00	Disclosure SEC source: 0001437749-22-016432 · rdgdoc.xml · nonDerivative · entry 1 DeMont Ross D · CIK 0001360838 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,942 Read SEC document
May 20, 2019 Filed May 23, 2019 08:30 UTC	SIERRA MONITOR CORP /CA/ SRMC · Entity 157272	Disposition to issuerCOMMON STOCK	200,000	$3.25	$650,000.00	Disclosure SEC source: 0001493152-19-008135 · ownership.xml · nonDerivative · entry 1 DeMont Ross D · CIK 0001360838 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Shares of Issuer common stock were cancelled and disposed at the effective time of the merger of Gateway Merger Sub, Inc. ("Merger Sub"), an indirect, wholly owned subsidiary of MSA Safety Incorporated ("MSA"), with and into the Issuer, pursuant to that certain Agreement and Plan of Merger dated March 28, 2019, among the Issuer, MSA and Merger Sub as a result of which Issuer became an indirect wholly owned subsidiary of MSA, in exchange for a cash payment of $3.25 per share. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.